Ernexa Therapeutics Inc.
ERNA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $1 | $1 | $1 | $2 |
| SG&A Expenses | $1 | $1 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $3 | $3 |
| Operating Income | -$2 | -$3 | -$3 | -$3 |
| % Margin | – | – | – | -269,700% |
| Other Income/Exp. Net | $1 | -$1 | -$5 | -$3 |
| Pre-Tax Income | -$1 | -$3 | -$8 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$3 | -$8 | -$6 |
| % Margin | – | – | – | -575,900% |
| EPS | -0.15 | -0.61 | -0.15 | -0.42 |
| % Growth | 75.4% | -306.7% | 64.3% | – |
| EPS Diluted | -0.15 | -0.61 | -0.15 | -0.42 |
| Weighted Avg Shares Out | 8 | 5 | 53 | 51 |
| Weighted Avg Shares Out Dil | 8 | 5 | 53 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | – | $3 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$2 | -$3 | -$2 |
| % Margin | – | – | – | -219,700% |